EU Clears Enhertu for Some Early Breast Cancer Patients
AstraZeneca and Daiichi Sankyo said the EU approved Enhertu as a single treatment after surgery for patients with residual HER2-positive disease.
Makkler Newsroom · Oct 27, 07:58 PM · 1 min read
